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Abstract 
Internal mammary lymph nodes as solitary site of recurrent ovarian cancer have not been 
previously described. In this case report, 3 cases of late and very late isolated recurrence 
in internal mammary lymph nodes are presented. 18F-FDG-PET/CT allowed the diagnosis 
which was suspected by the increase of the serum CA-125 level in 2 out of 3 cases. Local 
treatment, consisting of surgery (in 2 patients) and radiation therapy (in 1 patient), 
permitted an optimal long-term disease control. 
Introduction 
Recurrent epithelial ovarian carcinoma has a poor prognosis and is almost always fatal 
[1, 2]. The most frequent relapse site involves the peritoneal cavity and the 
infradiaphragmatic lymph nodes. Outside the abdomen, the most frequent metastatic 
sites are the pleura and the mediastinal lymph nodes [3, 4]. Although nodal metastases are 
well known in the course of epithelial ovarian carcinoma, solitary lymph node relapses are 
rarely described. The cervical, supraclavicular, groin and axillary areas are unusual sites of 
isolated lymph node involvement [5]. In a retrospective study evaluating 640 ovarian 
cancer patients, the incidence of isolated lymph node relapses was 4.2%. Prognosis of 
isolated lymph node relapse seems better than that of metastatic recurrence at other sites 
and in the event of an asymptomatic relapse, immediate or delayed therapy should be 
assessed [6]. 
Recurrence of ovarian carcinoma is commonly suspected when there is a progressive 
increase of the serum CA-125 level, but it does not allow differentiation between localized  
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and diffuse tumor spread. CT scan is the imaging technique of choice, but its capability to 
detect residual tumor is limited in case of small metastases, such as peritoneal, mesenteric 
and omental recurrences. CT has also limitations in differentiating residual malignant 
lesions from benign postoperative changes.
 18F-FDG-PET can detect residual tumor with a 
higher accuracy than CT and even with a higher sensitivity than the tumor markers CA-
125 [7, 8]. Recently, we have observed internal mammary lymph node metastases 
diagnosed by 
18F-FDG-PET/CT as a solitary recurrence site in 3 ovarian cancer patients. 
Case Reports 
Case 1 
A 65-year-old woman had been treated by total abdominal hysterectomy, bilateral salpingo-
oophorectomy, pelvic lymphadenectomy and omentectomy followed by chemotherapy (carboplatin and 
cyclophosphamide) for ovarian papillary serous adenocarcinoma stage IC in 1997. At her annual follow-
up, 9 years later (May 2006), the serum CA-125 level was increased (83 U/ml, normal value <35 U/ml). 
A PET/CT scan showed increased 
18F-FDG uptakes in the bilateral internal mammary lymph nodes (fig. 
1a, b), with suspected infiltration of the right side of the sternum (fig. 1c) as the unique pathological 
finding. A CT scan confirmed an abnormal left internal mammary lymph node of 1.7 cm in size and a 
thickening of the right parasternal tissue. She was treated with 7 courses of chemotherapy (carboplatin 
plus gemcitabine). At the end of the treatment, the serum CA-125 level was stable (75 U/ml) and a CT 
scan confirmed stable disease. External radiation therapy was administered to the bilateral internal 
mammary lymph node chains at a total dose of 4,680 cGy. One month later, there was a complete 
normalization of the CA-125 value. PET/TC was performed 4 months after the end of the radiation 
therapy and showed a reduction of the 
18F-FDG uptake in the right internal mammary lymph node 
(SUV max. 6 vs. 11) and a complete normalization in the contralateral lymph node. 
In November 2007, she was retreated with chemotherapy (6 courses of carboplatin) for disease 
progression in the internal mammary lymph nodes and the sternum. In July 2008, she developed 2 
subcentimetric brain metastases that were treated with stereotaxic radiosurgery, obtaining a complete 
remission. In September 2008, an increase of the serum CA-125 level occurred (265 U/ml) and the 
18F-
FDG-PET/CT scan showed multiple pathological uptakes in the supradiaphragmatic lymph nodes 
(bilateral supraclavicular, internal mammary chains and mediastinal). She was treated with 6 courses of 
carboplatin + paclitaxel and the serum CA-125 level was normalized. During 2010, disease progression 
was further documented and monochemotherapy with pegylated doxorubicin was started. On 
December 31, 2010, she was still on treatment. 
Case 2 
A 47-year-old woman had been treated by total abdominal hysterectomy, bilateral salpingo-
oophorectomy and lombo-aortic lymphadenectomy followed by chemotherapy (cisplatin and 
cyclophosphamide) for ovarian papillary serous carcinoma stage III in 1991. Subsequently, she first 
received anterior sigmoid resection for pelvic relapse and adjuvant carboplatin (1996), and secondly, 
chemotherapy with cisplatin + paclitaxel, followed by liver dissections for liver metastases and 
carboplatin + topotecan chemotherapy (1998). During these treatments, there was no evidence of 
disease. In 2001, at a follow-up examination, a right supraclavicular lymph node was palpable. In 
absence of other signs of localizations, she was treated with gemcitabine + vinorelbine over a 4-month 
period. The patient experienced partial remission and subsequently, she was submitted for dissection of 
the right supraclavicular lymph node. The histological examination showed a poorly differentiated 
adenocarcinoma. Radiation therapy was delivered postoperatively. In December 2002, a PET/CT carried 
out during a follow-up examination, showed an increased 
18F-FDG uptake in a left internal mammary 
lymph node (fig. 2); the serum CA-125 level had a normal value. She was operated on and a lymph node 
metastasis was removed and histologically confirmed (poorly differentiated adenocarcinoma). No 
postoperative treatment was administered. In January 2006, a PET/CT showed an increased 
18F-FDG 
uptake in 3 supradiaphragmatic nodules located in the right anterior costophrenic sinus. She was  
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treated with supradiaphragmatic lymphadenectomy and partial diaphragm resection; 3 out of 14 lymph 
nodes were massively infiltrated by a poorly differentiated adenocarcinoma of ovarian origin. At the last 
follow-up examination (December 2010), almost 5 years later, the patient was well and showed no 
evidence of disease. 
Case 3 
A 51-year-old woman had been treated by total abdominal hysterectomy, bilateral salpingo-
oophorectomy and omentectomy, followed by chemotherapy (carboplatin and paclitaxel) for ovarian 
papillary serous carcinoma stage IIIB in 2002. At her annual follow-up, 6 years later, the serum CA-125 
level showed an increase above the normal level (>35 U/ml). A PET/CT scan revealed an increased 
18F-
FDG uptake in the right internal mammary lymph nodes and the cardiophrenic nodule. She was treated 
with a cardiophrenic nodule excision. The nodule showed infiltration by a papillary adenocarcinoma of 
ovarian origin. Thus, 1 month later, she was submitted for right internal mammarian 
lymphoadenectomy; the histological examination confirmed a papillary adenocarcinoma. From April to 
July 2009, she was treated with 6 courses of carboplatin and paclitaxel. The serum CA-125 level was 
within the normal range. At the last follow-up visit, in September 2010, she was well and showed no 
signs of recurrent disease. 
Conclusion 
We have been unsuccessful in finding reports on internal mammary lymph nodes 
metastases from ovarian cancer in the recent literature. In this case report, we have 
presented 3 cases of recurrent ovarian cancer in which PET/CT detected internal 
mammary lymph node metastases as unique site of disease, 6, 9 and 11 years after the 
primary surgical operation, respectively. In the first and third case, PET/CT confirmed 
the recurrence suspected by the increase of the serum CA-125 level; in the second case, 
PET/CT was carried out as a follow-up examination in absence of symptoms or increased 
serum CA-125 levels. In these 3 patients, the PET/CT scan has enabled a local therapeutic 
approach: a surgical treatment in two patients and radiation therapy in 1 patient, 
permitting a local control of the disease. At, respectively, 4.5, 8 and 2 years after the 
diagnosis of internal mammary lymph node metastases our patients are still alive. Two 
cases have no evidence of disease and 1 case shows persistence of disease. 
To our knowledge, this is the first report on internal mammary lymph nodes as a site 
of late and very late solitary ovarian cancer recurrence and on the determining role of 
PET/CT scan for the diagnosis of isolated tumor involvement and therapeutic decision-
making. Surgical dissection or radical radiotherapy have allowed to obtain optimal disease 
control in all 3 patients. 
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Fig. 1. Case 1. FDG-PET/CT scan shows increased uptakes in bilateral internal mammary lymph nodes 
(a and b) with involvement of right side of the sternum (c). 
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Fig. 2. Case 2. FDG-PET/CT scan shows pathological uptake in left internal mammary lymph nodes. 
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